drugset / Trial / NCT00000438
Naltrexone Treatment for Alcoholism
Phase 4
Completed
192 enrolled
Johns Hopkins University
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedTreatment
Summary
This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2003-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | — | — |